Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Monday’s Trading Day
66.50 +2.74 / +4.30%
Data as of Sep 29
Day’s Change
Tuesday’s Pre-Market   Switch to standard view »
66.50 0.00 / 0.00%
 
Volume: 110.00
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.3B

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in cellular metabolism to transform the lives of patients with cancer and inborn errors of metabolism, or IEMs, which are a subset of orphan genetic metabolic diseases. The company's products include IDH1 AND IDH2, PKR, II D-2 hydroxyglutaric aciduria, AG-221, AG-120 and AG-348. Agios Pharmaceuticals was founded by Lewis Clayton Cantley, Tak W. Mak and Craig B. Thompson on August 7, 2007 and is headquartered in Cambridge, MA.

Contact Information

Agios Pharmaceuticals, Inc.
38 Sidney Street
Cambridge Massachusetts 02139-4169
P:(617) 649-8600
Investor Relations:
(617) 649-8608

Employees

Shareholders

Individual stakeholders41.49%
Mutual fund holders32.95%
Other institutional22.04%

Top Executives

David Paul SchenkeinPresident, Chief Executive Officer & Director
John Duncan HiggonsChief Operating Officer
Glenn GoddardSenior Vice President-Finance
Shin-San Michael SuSenior Vice President-Research & Development
Scott BillerChief Scientific Officer

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.